Copper, ceruloplasmin, superoxide dismutase and iron parameters in Parkinson's disease

Pharmacology and Toxicology

Volumn 85, Issue 5, 1999, Pages 239-243

  Tórsdóttir, Gudlaug ^a,b   Kristinsson, Jakob ^a   Sveinbjörnsdóttir, Sigurlaug ^c   Snaedal, Jón ^b   Jóhannesson, Torkell ^a  

^a UNIVERSITY OF ICELAND   (Iceland)

^b Reykjavik Hospital   (Iceland)

^c LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

Author keywords

[No Author keywords available]

Indexed keywords

CERULOPLASMIN; COPPER; DECARBOXYLASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; FERRITIN; IRON; LEVODOPA; SUPEROXIDE DISMUTASE; TRANSFERRIN;

ADULT; AGED; ARTICLE; CERULOPLASMIN BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; COPPER BLOOD LEVEL; COPPER METABOLISM; ENZYME ACTIVITY; ERYTHROCYTE; FEMALE; HUMAN; HUMAN CELL; IRON BLOOD LEVEL; IRON METABOLISM; MALE; OXIDATION; PARKINSON DISEASE; PRIORITY JOURNAL;

EID: 0032734745     PISSN: 09019928     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0773.1999.tb02015.x     Document Type: Article

References (19)

1. Bostantjopoulou, S., G. Kyriazis, Z. Katsarou, G. Kiosseoglou, A. Kazis & G. Mentenopoulos: Superoxide dismutase activity in early and advanced Parkinson's disease. Functional Neurology 1997, 12, 63-68.
2. Boyett, J. D., H. P. Lehmann & M. F. Becler: Automated assay of ceruloplasmin by kinetic analysis of o-dianisidine oxidation. Acta Clin. Chem. 1976, 69, 233-241.
3. Dexter, D. T., F. R. Wells, A. J. Lees, F. Agid, Y. Agid, P. Jenner & C. D. Marsden: Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J. Neurochem. 1989, 52, 1830-1836.
4. Gutteridge, J. M. C.: Antioxidant properties of caeruloplasmin towards iron- and copper-depentent oxygen radical formation. FEBS 0491, 1983, 157, 37-40.
5. Halliwell, B.: Reactive oxygen species and the central nervous system. J. Neurochem. 1992, 59, 1609-1623.
6. Halliwell, B.: Free radicals and antioxidants: A personal view. Nutrition Revs. 1994, 52, 253-265.
7. Harris, R. L., Y. Takahashi, H. Miyajima, M. Serizawa, R. T. A. McGillivary & J. D. Gitlin: Aceruloplasminemia: Molecular characterization of this disorder of iron metabolism. Proc. Natl. Acad. Sci. 1995, 92, 2539-2543.
8. Hoehn, M. M. & M. D. Yahr: Parkinsonism: onset, progression and mortality. Neurology 1967, 17, 427-442.
9. Loeffler, D. A., A. J. DeMaggio, P. L. Juneau, C. M. Brickman, G. A. Mashour, J. H. Finkelman, N. Pomara & P. A. LeWitt: Ceruloplasmin is increased in cerebrospinal fluid in Alzheimer's disease but not Parkinson's disease. Alzheimer Disease and Associated Disorders 1994, 8, 190-197.
10. Loeffler, D. A., P. A. LeWitt, P. L. Juneau, A. A. F. Sima, H.-U. Nguyen, A. J. DeMaggio, C. M. Brickman, G. J. Brewer, R. D. Dick, M. D. Troyer & L. Kanaley: Increased regional brain concentration of ceruloplasmin in neurodegenerative disorders. Brain Res 1996, 738, 265-274.
11. Logroscino, G., K. Marder, J. Graziano, G. Freyer, V. Slavkovich, N. Loiacono, L. Cote & R. Mayeux: Altered systemic iron metabolism in Parkinson's disease. Neurology 1997, 49, 714-717.
12. Nebot, C., P. Moutet, P. Huet, J. Z. Xu, J. C. Yadan & J. Chaudiere: Spectrophotometric assay of superoxide dismutase activity based on the activated autoxidation of a tetracyclic catechol. Anal. Biochem. 1993, 214, 442-451.
13. Rybicki, B. A., C. C. Johnson, J. Uman & J. M. Gorell: Parkinson's disease mortality and the industrial use of heavy metals in Michigan. Movement Disorders 1993, 8, 87-92.
14. Saggu, H., J. Cooksey, D. Dexter, F. R. Wells, A. Lees, P. Jenner & C. D. Marsden; A selective increase in particulate superoxide dismutase activity in Parkinsonian substantia nigra. J. Neurochem. 1989, 53, 692-697.
15. Shull, S., N. H. Heintz, M. Periasamy, M. Manohar, Y. M. W. Janssen, J. P. Marsh & B. T. Mossman: Differential regulation of antioxidant enzymes in response to oxidants. J. Biol. Chem. 1991, 266, 24398-24403.
16. Snaedal, J., J. Kristinsson, S. Gunnarsdóttir, Á. Ólafsdóttir, M. Baldvinsson & T. Jóhannesson: Copper, ceruloplasmin and superoxide dismutase in patients with Alzheimer's disease. Dementia 1998, 9, 239-242.
17. Spencer, J. P. E., A. Jenner, O. J. Aruoma, P. T. Evans, H. Kaur, D. T. Dexter, P. Jenner, A. J. Lees, D. C. Marsden & B. Halliwell: Intense oxidative DNA damage promoted by L-DOPA and its metabolites. Implications for neurodegenerative disease. FEBS Letters 1994, 353, 246-250.
18. Sziráki, I., K. P. Mohanakumar, P. Rauhala, H. G. Kim, K. J. Yeh & C. C. Chiueh: Manganese: A transition metal protects nigrostriatal neurons from oxidative stress in the iron-induced animal model of Parkinsonism. Neuroscience 1998, 85, 1101-1111.
19. Urakami, K., K. Sano, E. Matsushima, A. Okada, H. Saito, K. Takahashi, J. Ikebuchi, T. Mura & S. Ikawa: Decreased superoxide dismutase activity in erythrocyte in Parkinson's disease. Jap. J. Psychiat. Neurol. 1992, 46, 933-936.